The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis
Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.
Saurabh Chandan1, Babu P Mohan2, Shahab R Khan3, Antonio Facciorusso4, Daryl Ramai5, Lena L Kassab6, Neil Bhogal7, Ravishankar Asokkumar8, Gortrand Lopez-Nava8, Stephanie McDonough2, Douglas G Adler9
Author information
1Division of Gastroenterology and Hepatology, CHI Creighton University Medical Center, Omaha, NE, USA.
2Division of Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, 30N 1900E 4R118, Salt Lake City, UT, 84132, USA.
3Section of Gastroenterology, Rush University Medical Center, Chicago, IL, USA.
4Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.
5Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, USA.
6Internal Medicine, Mayo Clinic, Rochester, MI, USA.
7Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.
8Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore.
9Division of Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, 30N 1900E 4R118, Salt Lake City, UT, 84132, USA. Douglas.adler@hsc.utah.edu.
Abstract
Intragastric balloon (IGB) therapy has shown efficacy in weight loss but its role in NAFLD remains unknown. We conducted a systematic review and meta-analysis to evaluate the efficacy of IGB in NAFLD. Meta-analysis was performed to estimate the pooled proportion of patients with improvement in steatosis as determined by imaging and histology following IGB placement. Nine studies were included in our analysis. Four hundred forty-two IGBs were placed. Improvement in steatosis was seen in 79.2% of patients and NAS in 83.5% of patients, and HOMA-IR score improved in 64.5% of patients. A reduction in liver volume by CT scan was noticed in 93.9% of patients undergoing IGB placement. IGB is an effective and safe short-term therapeutic modality for patients with NAFLD.